<DOC>
	<DOCNO>NCT00089648</DOCNO>
	<brief_summary>The purpose study test whether sunitinib ( SU011248 ) activity safe patient renal cell carcinoma ( RCC ) fail prior therapy bevacizumab ( Avastin ) -based treatment .</brief_summary>
	<brief_title>SU011248 In The Treatment Of Patients With Bevacizumab ( Avastin ) -Refractory Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically proven renal cell carcinoma clear cell histology metastases Evidence measurable disease Radiographic evidence disease progression within 3 month completion bevacizumabbased treatment Prior radical partial nephrectomy Prior treatment antiangiogenic therapy bevacizumab Prior systemic treatment RCC &gt; 2 regimen History know brain metastasis Serious acute chronic illness recent history significant cardiac abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>